Related Experiment Videos
HRE 664, a new parenteral penem. I. Antibacterial activity in vitro
Abstract:
The new penem antibiotic HRE 664 displays potent antibacterial activity in vitro against a broad spectrum of clinically relevant bacterial strains including Gram-negative and Gram-positive aerobes and anaerobes. With an MIC 90% of 0.43 micrograms/ml, it is also active against methicillin-resistant staphylococci. HRE 664 is extremely stable against beta-lactamases, it binds preferentially to the penicillin-binding proteins 2, 3, 5 and 6 of Escherichia coli.
Insights
The novel penem antibiotic HRE 664 shows strong antibacterial effects against many bacteria, including resistant strains. It is highly stable against beta-lactamases, offering a promising new treatment option.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- The rise of antibiotic resistance necessitates the development of new antibacterial agents.
- Beta-lactamase enzymes pose a significant challenge to existing antibiotic therapies.
Purpose of the Study:
- To evaluate the in vitro antibacterial activity and characteristics of the novel penem antibiotic HRE 664.
- To determine the spectrum of activity and mechanism of action of HRE 664.
Main Methods:
- In vitro susceptibility testing against a wide range of bacterial strains.
- Determination of the Minimum Inhibitory Concentration (MIC 90%).
- Assessment of stability against beta-lactamase enzymes.
- Investigation of penicillin-binding protein (PBP) interactions.
Main Results:
- HRE 664 demonstrated potent in vitro activity against Gram-negative and Gram-positive aerobes and anaerobes.
- The antibiotic exhibited significant activity against methicillin-resistant staphylococci (MRSA).
- HRE 664 showed remarkable stability when exposed to beta-lactamase enzymes.
- Preferential binding of HRE 664 to Escherichia coli penicillin-binding proteins 2, 3, 5, and 6 was observed.
Conclusions:
- HRE 664 is a potent new penem antibiotic with broad-spectrum activity.
- Its stability against beta-lactamases and activity against resistant pathogens make it a promising candidate for further development.
- Understanding its PBP binding profile provides insight into its mechanism of action.